Ted Hisokawa
January 14, 2025 08:13
Working with industry giants, NVIDIA aims to use AI and accelerated computing to advance genomics, drug discovery, and healthcare and transform the $10 trillion healthcare industry.
NVIDIA announced strategic partnerships with leading organizations in healthcare and life sciences aimed at transforming genomics, drug discovery, and healthcare services. According to the NVIDIA Newsroom, the collaboration involves industry giants such as IQVIA, Illumina, Mayo Clinic, and Arc Institute to leverage NVIDIA’s advanced AI and accelerated computing technologies.
Medical innovation through AI
The convergence of AI, accelerated computing, and biological data is positioning healthcare as a leading technology industry. The goal of this collaboration is to leverage NVIDIA’s capabilities to develop solutions that can significantly improve human health. These solutions include AI agents to accelerate clinical trials, AI models for drug discovery and digital pathology, and AI robots for surgery and surgical assistance.
“AI presents an extraordinary opportunity to advance healthcare and life sciences with tools that help providers detect disease earlier and discover new treatments faster,” said Kimberly Powell, vice president of Healthcare at NVIDIA. He said. This initiative is expected to create AI factory opportunities worth hundreds of billions of dollars.
IQVIA’s AI-Driven Innovation
IQVIA, a leader in clinical research services and healthcare intelligence, is leveraging NVIDIA’s AI Foundry service to build custom foundation models. These models will be developed using more than 64 petabytes of data with the goal of accelerating research and clinical development. The company is committed to ensuring that its AI-powered capabilities adhere to privacy, compliance, and patient safety standards.
Illumina’s Genomic Advances
Illumina, known for its DNA sequencing technology, is collaborating with NVIDIA to advance genomics for drug discovery. This partnership will allow Illumina to integrate NVIDIA’s AI tools into its Multiomics analysis software, expanding access to genomic insights for researchers and pharmaceutical companies around the world. The collaboration also aims to advance multi-omics data analysis and develop new biology-based models.
Pathology Innovations at Mayo Clinic
Mayo Clinic will use technology from NVIDIA to accelerate development of pathology-based models. Digital pathology platforms containing massive data sets of whole slide images and patient records will benefit from NVIDIA’s DGX Blackwell system and medical imaging platform MONAI. This partnership is focused on advancing personalized diagnostic and treatment strategies.
AI model development at Arc Institute
Arc Institute is collaborating with NVIDIA to develop AI models to advance biomedical discoveries. By combining expertise in biology and machine learning, the partnership aims to create scalable foundational models that can generalize across a variety of biological modalities. NVIDIA’s support includes providing the BioNeMo platform and expertise in large-scale model development.
Through these partnerships, NVIDIA and its partners are poised to make significant advances in the healthcare and life sciences industries, potentially transforming the way we understand and treat disease globally.
Image source: Shutterstock